CD28 and neoplasm: Perhaps the most critical modification to the CAR was the incorporation of the CD28 transmembrane domain to the 4-1BB costimulatory domain, which allowed for durable anti-tumor activity and improved T-cell expansion in recursive tumor cell killing assays.